Presidio Partners
Presidio Partners is a San Francisco–based venture investment firm that emphasizes active portfolio management and company-building across information technology, life sciences, and energy technology. The firm leverages 25+ years of venture and operating experience (formerly as CMEA Capital), a data-and-technology orientation, and practices intended to increase transparency and accountability (for example, assigning two Presidio team members to each major investment).
Presidio Partners
Services
Equity venture investments
Provision of venture capital equity to growth-stage companies across IT, life sciences, and energy technology.
Active portfolio management & company-building
Ongoing operational engagement with portfolio companies to improve business models, operations, and financing over the life of the investment.
Strategic and sector guidance
Sector- and stage-specific strategic guidance drawing on deep experience in IT, life sciences, and energy technology.
Governance, accountability & mentorship (two-person coverage)
Assigning two Presidio team members to every major investment to provide two perspectives, increase accountability, and support collaboration.
Pharmaceutical development experimentation
Exploration of novel approaches to pharmaceutical development aimed at increasing development efficiency.
Equity venture investments
Provision of venture capital equity to growth-stage companies across IT, life sciences, and energy technology.
Active portfolio management & company-building
Ongoing operational engagement with portfolio companies to improve business models, operations, and financing over the life of the investment.
Strategic and sector guidance
Sector- and stage-specific strategic guidance drawing on deep experience in IT, life sciences, and energy technology.
Governance, accountability & mentorship (two-person coverage)
Assigning two Presidio team members to every major investment to provide two perspectives, increase accountability, and support collaboration.
Pharmaceutical development experimentation
Exploration of novel approaches to pharmaceutical development aimed at increasing development efficiency.
Portfolio
Press items on product launches, patents, and a $33M Series D funding round noted on Presidio site.
#Life Sciences / Agricultural biotechnology
Noted on the site: completion of acquisition of Spitfire Pharma and development milestone toward a single-dose intranasal COVID-19 vaccine.
#Biotechnology / Vaccines
Press items reference executive team announcements and capital raises ($23M and $40M funding rounds reported in news items).
#Energy technology / Solar
A123 Systems completed a $5M equity investment (Series B) and Wildcat later raised over $20M in Series C financing according to Presidio content.
#Energy technology / Advanced materials for batteries
Multiple news items reference Series C financing, loan facility, patent issuance, and FDA approvals for products.
#Pharmaceuticals
Press items on product launches, patents, and a $33M Series D funding round noted on Presidio site.
#Life Sciences / Agricultural biotechnology
Noted on the site: completion of acquisition of Spitfire Pharma and development milestone toward a single-dose intranasal COVID-19 vaccine.
#Biotechnology / Vaccines
Press items reference executive team announcements and capital raises ($23M and $40M funding rounds reported in news items).
#Energy technology / Solar
A123 Systems completed a $5M equity investment (Series B) and Wildcat later raised over $20M in Series C financing according to Presidio content.
#Energy technology / Advanced materials for batteries
Multiple news items reference Series C financing, loan facility, patent issuance, and FDA approvals for products.
#Pharmaceuticals